Research ExplorerPublicationsThe impact of lymph node dissection and positive lymph nodes...

The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pTnon-metastatic renal cell carcinoma treated with radical nephrectomy

Standard

The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pTnon-metastatic renal cell carcinoma treated with radical nephrectomy. / Marchioni, Michele; Bandini, Marco; Pompe, Raisa; Martel, Tristan; Tian, Zhe; Shariat, Shahrokh F; Kapoor, Anil; Cindolo, Luca; Briganti, Alberto; Schips, Luigi; Capitanio, Umberto; Karakiewicz, Pierre I.

In: BJU INT, Vol. 121, No. 3, 03.2018, p. 383-392.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Marchioni, M, Bandini, M, Pompe, R, Martel, T, Tian, Z, Shariat, SF, Kapoor, A, Cindolo, L, Briganti, A, Schips, L, Capitanio, U & Karakiewicz, PI 2018, 'The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pTnon-metastatic renal cell carcinoma treated with radical nephrectomy', BJU INT, vol. 121, no. 3, pp. 383-392. https://doi.org/10.1111/bju.14024

APA

Marchioni, M., Bandini, M., Pompe, R., Martel, T., Tian, Z., Shariat, S. F., Kapoor, A., Cindolo, L., Briganti, A., Schips, L., Capitanio, U., & Karakiewicz, P. I. (2018). The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pTnon-metastatic renal cell carcinoma treated with radical nephrectomy. BJU INT, 121(3), 383-392. https://doi.org/10.1111/bju.14024

Vancouver

Marchioni M, Bandini M, Pompe R, Martel T, Tian Z, Shariat SF et al. The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pTnon-metastatic renal cell carcinoma treated with radical nephrectomy. BJU INT. 2018 Mar;121(3):383-392. https://doi.org/10.1111/bju.14024

Bibtex

@article{f22a34da564048f2a5a4b77272f87f9e,
title = "The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pTnon-metastatic renal cell carcinoma treated with radical nephrectomy",
abstract = "OBJECTIVE: To assess the effect of lymph node dissection (LND), number of removed nodes (NRN), and number of positive nodes (NPN), on cancer-specific mortality (CSM) in contemporary vs historical patients with pT2-3NanyM0renal cell carcinoma (RCC) treated with radical nephrectomy (RN).PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2001-2013), we identified patients with non-metastatic pT2-3NanyRCC who underwent RN with or without LND. Kaplan-Meier analyses and multivariable Cox regression models with propensity score weighting for inverse probability of treatment were used.RESULTS: Of 25 357 patients, 24.8% underwent LND (2001-2007: 3 167 patients vs 2008-2013: 3 133 patients). The median NRN was 3 (interquartile range [IQR]: 1-7). Positive nodes were identified in 17.1%: 9.3% of pT2and 21.6% of pT3patients, who underwent LND. The median NPN was 2 (IQR: 1-3). In multivariable models, LND did not decrease CSM (hazard ratio [HR] 1.29; P < 0.001). LND extent, defined as NRN, did not decrease CSM (HR 0.94; P = 0.3). Finally, multivariable models testing the effect of NPN showed increased CSM in pT3but not in pT2patients (HR 1.29 and 1.58, P = 0.02 and P = 0.1, respectively). NRN exerted a protective effect on CSM in patients with positive nodes (HR 0.98; P = 0.007).CONCLUSION: In contemporary and historical patients LND or its extent do not protect from CSM. However, the NPN increases the rate of CSM in pT3patients. Consequently, LND and its extent appear to have little if any therapeutic value in pT2-3NanyM0patients, besides its prognostic impact. High-risk non-metastatic patients may represent a target population for a multi-institutional prospective trial.",
keywords = "Journal Article",
author = "Michele Marchioni and Marco Bandini and Raisa Pompe and Tristan Martel and Zhe Tian and Shariat, {Shahrokh F} and Anil Kapoor and Luca Cindolo and Alberto Briganti and Luigi Schips and Umberto Capitanio and Karakiewicz, {Pierre I}",
note = "{\textcopyright} 2017 The Authors BJU International {\textcopyright} 2017 BJU International Published by John Wiley & Sons Ltd.",
year = "2018",
month = mar,
doi = "10.1111/bju.14024",
language = "English",
volume = "121",
pages = "383--392",
journal = "BJU INT",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pTnon-metastatic renal cell carcinoma treated with radical nephrectomy

AU - Marchioni, Michele

AU - Bandini, Marco

AU - Pompe, Raisa

AU - Martel, Tristan

AU - Tian, Zhe

AU - Shariat, Shahrokh F

AU - Kapoor, Anil

AU - Cindolo, Luca

AU - Briganti, Alberto

AU - Schips, Luigi

AU - Capitanio, Umberto

AU - Karakiewicz, Pierre I

N1 - © 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.

PY - 2018/3

Y1 - 2018/3

N2 - OBJECTIVE: To assess the effect of lymph node dissection (LND), number of removed nodes (NRN), and number of positive nodes (NPN), on cancer-specific mortality (CSM) in contemporary vs historical patients with pT2-3NanyM0renal cell carcinoma (RCC) treated with radical nephrectomy (RN).PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2001-2013), we identified patients with non-metastatic pT2-3NanyRCC who underwent RN with or without LND. Kaplan-Meier analyses and multivariable Cox regression models with propensity score weighting for inverse probability of treatment were used.RESULTS: Of 25 357 patients, 24.8% underwent LND (2001-2007: 3 167 patients vs 2008-2013: 3 133 patients). The median NRN was 3 (interquartile range [IQR]: 1-7). Positive nodes were identified in 17.1%: 9.3% of pT2and 21.6% of pT3patients, who underwent LND. The median NPN was 2 (IQR: 1-3). In multivariable models, LND did not decrease CSM (hazard ratio [HR] 1.29; P < 0.001). LND extent, defined as NRN, did not decrease CSM (HR 0.94; P = 0.3). Finally, multivariable models testing the effect of NPN showed increased CSM in pT3but not in pT2patients (HR 1.29 and 1.58, P = 0.02 and P = 0.1, respectively). NRN exerted a protective effect on CSM in patients with positive nodes (HR 0.98; P = 0.007).CONCLUSION: In contemporary and historical patients LND or its extent do not protect from CSM. However, the NPN increases the rate of CSM in pT3patients. Consequently, LND and its extent appear to have little if any therapeutic value in pT2-3NanyM0patients, besides its prognostic impact. High-risk non-metastatic patients may represent a target population for a multi-institutional prospective trial.

AB - OBJECTIVE: To assess the effect of lymph node dissection (LND), number of removed nodes (NRN), and number of positive nodes (NPN), on cancer-specific mortality (CSM) in contemporary vs historical patients with pT2-3NanyM0renal cell carcinoma (RCC) treated with radical nephrectomy (RN).PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2001-2013), we identified patients with non-metastatic pT2-3NanyRCC who underwent RN with or without LND. Kaplan-Meier analyses and multivariable Cox regression models with propensity score weighting for inverse probability of treatment were used.RESULTS: Of 25 357 patients, 24.8% underwent LND (2001-2007: 3 167 patients vs 2008-2013: 3 133 patients). The median NRN was 3 (interquartile range [IQR]: 1-7). Positive nodes were identified in 17.1%: 9.3% of pT2and 21.6% of pT3patients, who underwent LND. The median NPN was 2 (IQR: 1-3). In multivariable models, LND did not decrease CSM (hazard ratio [HR] 1.29; P < 0.001). LND extent, defined as NRN, did not decrease CSM (HR 0.94; P = 0.3). Finally, multivariable models testing the effect of NPN showed increased CSM in pT3but not in pT2patients (HR 1.29 and 1.58, P = 0.02 and P = 0.1, respectively). NRN exerted a protective effect on CSM in patients with positive nodes (HR 0.98; P = 0.007).CONCLUSION: In contemporary and historical patients LND or its extent do not protect from CSM. However, the NPN increases the rate of CSM in pT3patients. Consequently, LND and its extent appear to have little if any therapeutic value in pT2-3NanyM0patients, besides its prognostic impact. High-risk non-metastatic patients may represent a target population for a multi-institutional prospective trial.

KW - Journal Article

U2 - 10.1111/bju.14024

DO - 10.1111/bju.14024

M3 - SCORING: Journal article

C2 - 28940649

VL - 121

SP - 383

EP - 392

JO - BJU INT

JF - BJU INT

SN - 1464-4096

IS - 3

ER -